USA Indian firm Biocon has seen great success in the US in recent years, with two biosimilar launches and a range of generic medicines now available on the American market. In a recent interview with PharmaBoardroom, Biocon’s Commercial Head Global Generics & SVP Marketing Abhijit Zutshi outlined the company’s recipe…
USA KV Kumar, head of the Indian American International Chamber of Commerce, gives an account of the bilateral trade relations between India and the US and candidly speaks about the opportunities for Indian generic companies in the world’s largest pharmaceutical market. He addresses the need for supply chain diversification in light…
USA Abhijit Zutshi, commercial head global generics & SVP marketing at Indian firm Biocon highlights the challenges inherent in the US generics market, the process of setting up an affiliate in the US, and how Biocon’s level of vertical integration allows it to be highly competitive and stand out from the…
India The US generics market stood at USD 69 billion in 2018 and is expected to grow to USD 86 billion by 2022. Made with Visme Infographic Maker Abbreviated New Drug Applications (ANDAs), whereby a company seeks authorisation from the US FDA for a generic copy of a previously approved…
India A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in the USA, generic drugs play a vital role within US healthcare and have come a long way since their use…
Coronavirus The ongoing coronavirus outbreak and the subsequent shutdown of factories in China is having severe repercussions for Indian pharma manufacturers and could lead to global shortages. Shortages and Price Rises in India India depends on China for 80 percent of the Active Pharmaceutical Ingredients (APIs) that it uses in…
India Below is a selection of the top stories in Indian pharma from recent months, ranging from efforts to counter the coronavirus, to regulatory reform, the spike in USFDA warning letters to Indian pharma manufacturers, promising export markets, and the growth of the Indian domestic market. Repurposing HIV drugs to…
India Biocon, the first Indian company to have a biosimilar drug approved in the US, is taking another step forward with a new manufacturing facility and an expansion into the Australia and New Zealand markets. We see ourselves as a company that has great capabilities and is investing big time…
Opinion Eurasia Group’s Aditya Bhattacharji tackles three more key geopolitical issues that global pharma needs to be cognizant of: the world’s leading drug regulators becoming increasingly strident and active beyond national borders; the impact that greater awareness and work on climate change could have on the industry; and the risks surrounding…
India Regulation of medical devices in India has speedily evolved in the preceding two years. Before the introduction of the Medical Device Rules, 2017 (“MDR 2017”), the regulation of medical devices and drugs was inextricably linked. In the 18 months since the MDR 2017 has come into force, the biggest challenge…
India 2019 so far has witnessed a lot of activity in the pharma space, so much so that the e-pharmacy saga – a pressing development towards the close of 2018 – has taken a temporary backseat this year. Instead, the new stars of 2019 so far have been price regulation and…
India The Indian Government has had a busy 2019 so far with respect to healthcare regulation. From passing the controversial National Medical Commission Bill, 2019 through Parliament to releasing a digital health blueprint, the Indian Government has had a very clear vision for the future of healthcare in India. That vision…
See our Cookie Privacy Policy Here